Late-breaking trial published in BMJ proves the efficacy of Coala Heart Monitor as part of cryptogenic stroke management

IRVINE, Calif., Oct. 14, 2020 /PRNewswire/ -- Coala Life, a Swedish innovator in remote cardiac and respiratory monitoring, today announced the results of a late-breaking trial on cryptogenic stroke (stroke of unknown cause) patients. In the TEASE-study, recently published in the British Medical Journal (BMJ Open, Aug 2020), the Coala Heart Monitor was used to evaluate 100 patients after cryptogenic stroke. Patients were recruited from two stroke units in Sweden that underwent scheduled monitoring twice daily, and when symptoms occurred, for 28 days in everyday life.

The monitoring detected previously undiagnosed atrial fibrillation in 9% of the patients, at a mean of 19.7 days after stroke. Patient compliance to the Coala monitoring protocol exceeded 90%.

The prospective, real-world TEASE-study was led by Dr. Peter Magnusson, cardiologist at the Cardiology Clinic in Region Gavleborg, and with academic affiliations to the Karolinska Institute, Stockholm, and Uppsala University, Sweden.

"The study proves the efficacy of the Coala Heart Monitor in cryptogenic stroke patients with excellent patient compliance. We recommend a hand-held, non-invasive device like Coala Heart Monitor for long-term use as the main evaluation tool in the vast majority of cryptogenic stroke cases," comments Dr. Peter Magnusson.

The TEASE-study detected previously undiagnosed atrial fibrillation in 9% of cryptogenic stroke patients, using the non-invasive Coala Heart Monitor, at mean 20 days post stroke. In the CRYSTAL-AF study (NEJM, 2014) it took 6-months to detect AF in 8.9% of cryptogenic stroke patients by using an invasive insertable cardiac monitor.

The study is available with open access at: https://bmjopen.bmj.com/content/10/9/e037573.full

Source: Coala Life Inc.: Philip Siberg, (949) 590-7195
Email: [email protected]
URL: www.coalalife.com
Photos: https://press.coalalife.com/ 

Coala Life is a Swedish digital health venture focused on cardiac diagnostics and digital health. The company has developed a portfolio of patented CE- and FDA-cleared medical products and services for user-centered digital remote monitoring and analysis of the heart based on advanced and smart algorithms. Coala's solutions enable analysis, remote monitoring, more effective cardiac assessments and integrated care services, all in real time. Coala Life has raised in excess of USD 25 million and was named one of five global Cool Vendors by Gartner Group in 2018 and recognized in 2019 as of the 100 Global Leaders in Digital Health by the Journal of mHealth. Follow your Heart®. For more information see www.coalalife.com

SOURCE Coala Life

Related Links

http://www.coalalife.com